Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy manufacturing facility in the U.S.Profitability expected in 2026, driven by ...

SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial results and key ...

CARVYKTI ® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectively Over 5,000 patients treated to date Initiated commercial production of ...

“The breadth of data presented at ASH highlights our continuous innovation in both commercial and next-generation CAR-T platforms,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech.

We use Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share (which we sometimes refer to as “Adjusted EPS” or “ANI per Share”, respectively) as performance metrics. Adjusted Net Income ...